The major brands in China’s urinalysis market are URIT, DIRUI, AVE, etc. URIT produced China’s first urine analyzer in 1984. And after nearly 40 years’ strenuous cultivation, it pioneered the modular urine analysis workflow using deep learning artificial intelligence (AI) image recognition technology.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2023.

On July 27, the Indonesia-China Healthcare and Biotechnology Investment Forum, co-sponsored by the Embassy of the Republic of Indonesia in China and the China Committee of the Indonesian Chamber of Commerce and Industry, was held in Chengdu.

Siemens Healthineers AG today announces its results for the third quarter, ending June 30, of fiscal year 2023.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2023.

On 28 July, NHSA issued the "Notice on Providing Basic Medical Security for Urban and Rural Residents in 2023 by National Healthcare Security Administration, Ministry of Finance and State Taxation Administration".

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the BD Respiratory Viral Panel (RVP) for BD MAX™ System, a single molecular diagnostic combination test that identifies and distinguishes SARS-CoV-2, influenza A, influenza B, and Respiratory Syncytial Virus (RSV) in approximately two hours.

Revvity, Inc. (NYSE: RVTY), today reported financial results for the second quarter ended July 2, 2023.

According to the forecast of GHICapital, the market size of China's dPCR industry will still maintain a high growth rate from 2020 to 2024, and the market size will grow from 2.133 billion yuan to 7.011 billion yuan, at a CAGR of 34.65%.

Quest Diagnostics on Monday launched the first direct-to-consumer blood test to detect abnormal levels of beta amyloid, a key Alzheimer's disease protein that can appear years before dementia symptoms arise.

Amoy Diagnostics Co., Ltd (AmoyDx), a China-based innovative molecular diagnostics company, announced that it has entered into a Companion Diagnostic Collaboration Agreement with AstraZeneca, a global biopharmaceutical company.